Pricing Log in Create free account
Saturday 7 November 2026 Export URGN’s income statement to Excel — free account

Urogen Pharma

URGN Healthcare Biotechnology

Urogen Pharma’s revenue for fiscal 2025 (year ended December 2025) was $109.8 million, up 21.4% from fiscal 2024.

Revenue
+223.9%
EPS
+95.8%
Free cash flow
+64.0%
Total debt
+57.2%

Quarter to September 2026, against a year earlier

24.81 0.92 −3.58%
Market cap
$1.3B
P/E
0.0×
Fwd P/E
−161×
Dividend yield
—
F-score
2/9
Altman Z
−5.16
Beneish M
−1.42
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 4.52
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — 2 — — 1 2 1 1 2 1 —
Insider Ownership 17.92%

Capital & Financial Ratios $m

Size
Market Cap 1,260.00
Revenue ttm 250.25
Net income ttm (65.75)
Free cash flow ttm (132.05)
Net debt Q 100.06
Valuation
P/E 0.00
Forward P/E (161.00) (negative: loss-making)
Price / sales 5.01
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 3.40 (at or above 1.5: strong)
Debt / equity Q (1.53) (negative: negative equity)
Interest coverage Q 1.83
Growth
Revenue growth Q +223.85% (above 0%: growing)
Operating income growth Q +130.41% (above 0%: growing)
EPS, this year +88.44% (at or above 15%: strong)
EPS, next year A +777.03% (at or above 15%: strong)
Revenue, next year A +191.93% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +50.33% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 5.4×, against a ten-year median of 8.6×; over the ten years it ranged from 0.9× in 2022 to 812× in 2019.
P/S against its own 10 years 21.72%
10-year low 10-year high
EV/Sales against its own 10 years 33.55%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 138 238 122 92
Receivables 15 20 33 117
Inventory 6 9 16 25
Other — — — —
169 276 186 252
2023 2024 2025 Q'26
Payables 17 27 28 47
ST’ Debt — — — —
Other 4 8 5 8
31 46 46 74

Compound Annual Growth %

10y 5y 3y
Sales — 56.22% 19.49%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.05 Actual −0.03

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.66 −0.54 Beat by 0.12
Q1 FY26 −0.56 −0.47 Beat by 0.09
Q2 FY26 −0.38 −0.28 Beat by 0.10
Q3 FY26 0.05 −0.03 Miss by 0.08
Q4 FY26 0.28 — Reports 1 March 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.47) (0.28) (0.03) — —
’25 (0.92) (1.05) (0.69) (0.54) (3.19)
’24 (0.87) (0.82) (0.55) (0.80) (2.96)
’23 (1.30) (1.03) (0.68) (0.72) (3.55)
’22 (1.25) (1.18) (1.13) (1.22) (4.79)
’21 (1.17) (1.17) (1.35) (1.27) (4.96)
’20 (1.79) (1.44) (1.31) (1.38) (5.90)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 51 72 89 — —
’25 20 24 27 38 110
’24 19 22 25 25 90
’23 17 21 21 24 83
’22 14 17 16 18 64
’21 7 13 11 16 48
’20 — 0 3 8 12
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (45) (33) (15) — —
’25 (42) (40) (42) (38) (162)
’24 (32) (24) (28) (14) (97)
’23 (26) (20) (17) (13) (76)
’22 (24) (24) (18) (22) (88)
’21 (27) (19) (18) (20) (85)
’20 (36) (24) (25) (21) (106)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (45) (33) (15) — —
’25 (42) (40) (42) (38) (163)
’24 (32) (24) (28) (14) (97)
’23 (26) (20) (17) (13) (77)
’22 (24) (24) (18) (22) (88)
’21 (28) (19) (19) (20) (86)
’20 (36) (24) (26) (21) (107)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 18 8 1 0 12 48 64 83 90 110 250 +22.6% 321 523 664 +82.2%
Gross margin, % 99.84 92.65 (59.84) 100.00 91.45 89.27 88.11 88.68 90.18 88.66 91.41 (11.2) pt
EBT (2) (20) (76) (105) (125) (109) (108) (98) (124) (153) (64) +62.5%
EBT margin, % (11.07) (244.93) (6,696.10) (584,144.44) (1,060.34) (227.66) (167.86) (118.87) (137.22) (139.74) (25.64) (128.7) pt
Net income (2) (20) (76) (105) (128) (111) (110) (102) (127) (153) (66) +62.5%
Per share, $
Per share, $ Revenue 7.60 0.84 0.07 0.00 0.54 2.15 2.82 2.87 2.11 2.28 4.95 (12.5%)
Earnings (0.84) (2.14) (4.80) (5.12) (5.90) (4.96) (4.79) (3.55) (2.96) (3.19) (1.32) +16.0%
Cash flow 1.82 (0.98) (2.37) (3.46) (4.86) (3.80) (3.84) (2.65) (2.26) (3.38) (2.61) n/m
Capex (0.30) (0.03) (0.04) (0.02) (0.06) (0.03) (0.01) (0.01) (0.01) (0.01) 0.00 (35.3%)
Free cash flow 1.52 (1.01) (2.41) (3.48) (4.92) (3.83) (3.85) (2.66) (2.26) (3.38) (2.61) n/m
Book value 7.07 7.05 5.72 8.78 4.42 0.38 (3.92) (2.26) (0.21) (2.19) (2.48) n/m
Shares, m 2 10 16 21 22 22 23 29 43 48 50 +40.2%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 0.00 0.00 601.39 1,030.15 33.21 4.42 3.06 6.65 5.05 10.26 5.01 169.4
P/B 1.98 5.48 7.53 3.80 4.07 25.26 0.00 0.00 0.00 0.00 0.00 4.8
EV/Sales 0.00 0.00 511.34 812.12 24.60 2.55 3.01 6.17 3.77 10.30 5.41 137.4
EV/FCF 21.38 (30.72) (15.22) (7.57) (2.71) (1.43) (2.21) (6.67) (3.51) (6.95) (10.26) (5.6)
Cash, $m
Cash, $m Operating cash flow 4 (10) (37) (71) (106) (85) (88) (76) (97) (162) (132) n/m
Capex (1) 0 (1) 0 (1) (1) 0 0 0 0 0 (9.3%)
Free cash flow 3 (10) (38) (71) (107) (86) (88) (77) (97) (163) (132) n/m
Balance, $m
Balance, $m Working capital 19 67 89 129 94 92 105 138 230 140 178 +24.9%
Net debt (21) (73) (102) (145) (102) (90) (3) (39) (116) 0 100 n/m
Shareholders’ equity 16 69 90 180 96 8 (89) (65) (9) (105) (125) n/m
Returns, %
Returns, % ROA (9.15) (40.57) (84.48) (68.73) (79.22) (91.68) (85.98) (65.14) (54.68) (63.14) (28.78) (54.0) pt
ROIC 0.00 0.00 0.00 (193.80) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE (11.92) (47.16) (95.40) (77.77) (92.88) (211.55) 271.24 132.29 342.83 268.63 54.65 +280.6 pt
People
People Employees 33 46 78 173 187 195 200 201 235 291 — +27.4%
Revenue/emp, $m 0.53 0.18 0.01 0.00 0.06 0.25 0.32 0.41 0.38 0.38 — (3.7%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

Urogen Pharma vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
KARD KARDIGAN INC $1.3B — (loss-making) — — n/m — — 0.00% Compare
GHRS GH Research PLC $1.3B — (loss-making) — — n/m −66.62% (below 0%: shrinking) 0.00% 0.00% Compare
URGN Urogen Pharma $1.3B — (loss-making) — (loss-making) +223.85% (above 0%: growing) n/m +63.95% (above 0%: growing) 91.57% 9.36%
OMER Omeros Corporation $1.2B 9.8× 2.1× +35.46% (above 0%: growing) n/m +118.70% (above 0%: growing) 97.20% 0.26% Compare
DRTS Alpha Tau Medical Ltd. $1.2B — (loss-making) — — n/m −30.42% (below 0%: shrinking) 0.00% 0.00% Compare
LBRX LB Pharmaceuticals Inc $1.2B — (loss-making) — — n/m −579.03% (below 0%: shrinking) — 0.00% Compare
NKTR Nektar Therapeutics $1.2B — (loss-making) — (loss-making) −9.34% (below 0%: shrinking) n/m −65.73% (below 0%: shrinking) 100.00% (417.94%) Compare
SLN Silence Therapeutics PLC Sponsored ADR $1.2B — (loss-making) — (loss-making) +197.18% (above 0%: growing) n/m +106.95% (above 0%: growing) 97.39% 0.00% Compare
MNKD MannKind Corporation $1.2B — (loss-making) — (loss-making) +24.04% (above 0%: growing) n/m −267.69% (below 0%: shrinking) 0.00% (2.14%) Compare
Median of peers $1.2B — — +29.75% — −65.73% 48.60% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 30 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 4.31m 11.84m 264.04
2024 4.15m 1.94m 120.07
2023 4.64m 6.32m 169.11

Ownership

Directors and executive officers, together 4.80%
RTW Investments, LP 9.90%
Paradigm BioCapital Advisors LP 8.70%
Blackrock, Inc. 5.20%
Morgan Stanley 5.10%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Urogen Pharma (URGN) Latest News

4 Nov

Impact 4 · · GuruFocus.com
Impact 4 · · The Motley Fool transcript
Impact 4 · · GlobeNewswire
Impact 3 · · Moby
Impact 3 · · Simply Wall St.
Impact 3 · · MarketBeat transcript
Impact 3 · · The Motley Fool

28 Oct

Impact 4 · · GlobeNewswire

27 Oct

Impact 3 ·

20 Oct

Impact 4 · · Simply Wall St.

19 Oct

Impact 4 · · GlobeNewswire

30 Sep

Impact 4 · · Zacks

25 Sep

Impact 3 · · Simply Wall St.

23 Sep

Impact 4 ·

20 Aug

Impact 4 ·
Impact 4 ·

17 Aug

Impact 4 ·

12 Aug

Impact 3 · · The Motley Fool transcript

9 Aug

Impact 4 ·
Impact 3 ·

5 Aug

Impact 4 ·
Impact 4 · earnings
Impact 3 · · MarketBeat transcript
Impact 3 ·

17 Jul

Impact 3 · · Barchart

15 Jul

Impact 4 ·

8 Jul

Impact 4 ·

8 Jun

Impact 4 · · Simply Wall St.

2 Jun

Impact 3 · · GlobeNewswire

21 May

Impact 4 · · Simply Wall St.
stockrow.com/URGN · Data as of Nov 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com